【作者】 瞿伟；

【导师】 梁群；

【作者基本信息】 黑龙江中医药大学 ， 中医学， 2010， 硕士

【摘要】 目的：观察临床经验方益肺康心胶囊对慢性肺源性心脏病的治疗效果,及其对患者血浆PAF的影响。探讨其治疗慢性肺源性心脏病的机制。方法：本研究将符合入选标准的60例慢性肺源性心脏病患者随机分为两组,对照组30例,给予西医常规综合治疗,治疗组30例,在西医常规综合治疗的基础上,给予口服益肺康心胶囊,疗程为28天。比较两组临床疗效,并观察治疗前后血浆血小板活化因子水平、动脉血气分析结果、右心室射血前期与动脉血流加速时间的比值的变化。结果：治疗组总有效率为93.33%,对照组总有效率为70.00%,治疗组疗效优于对照组,差别有统计学意义(P<0.05)。两组治疗前各项指标均无显著性差异(P>0.05),一疗程后治疗组血浆血小板活化因子、动脉血气分析结果及右心室射血前期与动脉血流加速时间的比值治疗前后有显著差异(P<0.001,P<0.01,P<0.01),对照组血浆血小板活化因子、动脉血气分析结果及右心室射血前期与动脉血流加速时间的比值治疗前后有显著差异(P<0.001,P<0.01,P<0.01)。并且两组治疗后比较血浆血小板活化因子、动脉血气分析结果及右心室射血前期与动脉血流加速时间的比值也有显著差异(P<0.05)。结论：益肺康心胶囊能提高慢性肺源性心脏病患者的临床疗效,改善患者缺氧状态,降低患者血浆血小板活化因子含量,降低肺动脉高压,这可能是益肺康心胶囊治疗肺心病的机制之一。更多还原

【Abstract】 Objiective:To study the mechanism of YI-FEI-KANG-XIN capsule in patients with chronic pulmonary heart disease and to explore the effect of the serum level of platelet activating factor(PAF).To explore clinic curative effect of YI-FEI-KANG-XIN Capsule to the Chronic Pulmonary heart disease.Method:the 60 cases of patients with parative Group by stochastic process.These two groups of patients with CCP were given the routine treatment.Comparative Group would not take any Chinese medicine while Therapeutic Group take YI-FEI-KANG-XIN Capsule.to compare the changes of PAF,blood gas analysis (PaO2,PaCO2,SO2), RVPEP/AT between Therapeutic Group and Comparative Group.Result:Statistical signicance in the total response rate of Therapeutic Group (93.33%) compared with the Comparative Group (70%) (P< 0.05).After a course of treatment,the level of PAF,blood gas analysis and RVPEP/AT in Therapeutic Group were all significantly changed (P< 0.001,P < 0.01,P< 0.01). The level of PAF,blood gas analysis and RVPEP/AT in the Comparative Group were also significance changed (P<0.001,P<0.01,P< 0.01).After the treatment,statistical significance in the improvement of PAF, blood gas analysis and RVPEP/AT of Therapeutic Group and Comparative Group (P<0.05)Conclusion:The research indicated that YI-FEI-KANG-XIN Capsule could dramatically increas curative effect,improve hypoxia,decrease the level of PAF,delay the formation of pulmonary vascular remodeling and the development of pulmonary hypertension,therefore achieve the purpose of treatment of chronic pulmonary heart disease更多还原